Ellomay Capital (NYSE: ELLO) grants director 1,000 stock options at 19.60
Rhea-AI Filing Summary
Ellomay Capital Ltd. director Gilad Mamlok received an annual grant of stock options on August 1, 2026 under the 1998 Share Option Plan for Non-Employee Directors. The award covers 1,000 options to buy 1,000 Ordinary Shares at an exercise price of 19.60 per share, becoming exercisable on August 1, 2027 and expiring on August 1, 2036, subject to his continued board service on the exercise date.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Mamlok Gilad
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F1, F2 | 1,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 1,000 shares (Direct)
Footnotes (2)
- F1. On August 1, 2026, the Reporting Person received an annual grant of options under the terms and conditions set forth in the Issuer's 1998 Share Option Plan for Non-Employee Directors.
- F2. Subject to the Reporting Person serving as a member of the Issuer's Board of Directors on such date.
Key Figures
Stock options granted: 1,000 options
Exercise price: 19.60 per share
Underlying shares: 1,000 Ordinary Shares
+3 more
6 metrics
Stock options granted
1,000 options
Annual grant on August 1, 2026 to director Gilad Mamlok
Exercise price
19.60 per share
Conversion or exercise price for the granted stock options
Underlying shares
1,000 Ordinary Shares
Shares subject to the granted stock options
Total options after transaction
1,000 options
Total derivative holdings reported following this grant
Exercise date
August 1, 2027
Date from which the options become exercisable, subject to service
Expiration date
August 1, 2036
Final expiration date of the granted options
Key Terms
Stock Option (right to buy), 1998 Share Option Plan for Non-Employee Directors, exercise price, Ordinary Shares
4 terms
Stock Option (right to buy) financial
"security_title shows 'Stock Option (right to buy)' as the derivative security"
exercise price financial
"conversion_or_exercise_price of 19.6000 is the option exercise price per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Gilad Mamlok report for Ellomay Capital (ELLO)?
Gilad Mamlok reported an acquisition of stock options in Ellomay Capital. He received an annual grant of 1,000 options to buy Ordinary Shares as a non-employee director, reported as a derivative security on Form 4 with no sale of shares involved.
How many stock options were granted to Gilad Mamlok in Ellomay Capital (ELLO)?
Gilad Mamlok received 1,000 stock options from Ellomay Capital. Each option relates to one Ordinary Share, so the grant covers rights to acquire 1,000 Ordinary Shares as part of his annual compensation as a non-employee director.
What is the exercise price of Gilad Mamlok’s ELLO stock options and what do they cover?
The granted options carry an exercise price of 19.60 per share. They are stock options on Ordinary Shares, giving Gilad Mamlok the right to purchase 1,000 Ordinary Shares if he chooses to exercise them within the specified term.
When do Gilad Mamlok’s Ellomay Capital (ELLO) options vest and when do they expire?
Mamlok’s options become exercisable on August 1, 2027 and expire on August 1, 2036. This provides a roughly nine-year exercise window, beginning one year after the grant date, assuming the specified service condition is satisfied on the exercise date.
Are Gilad Mamlok’s ELLO stock options subject to any service condition?
Yes. Exercisability is subject to Gilad Mamlok serving on Ellomay’s Board on the August 1, 2027 exercise date. The footnote explains this condition, linking the ability to exercise the options to his continued role as a non-employee director.
Was the reported Ellomay Capital (ELLO) Form 4 transaction under a Rule 10b5-1 plan?
The Form 4’s Rule 10b5-1 checkbox is not marked as affirmative. The filing indicates the transaction as an annual option grant under the 1998 Share Option Plan for Non-Employee Directors rather than as activity under a Rule 10b5-1 trading plan.